Axsome Company Profile
What is the competitive landscape for AXSOME
AXSOME has three approved drugs.
There are two hundred and eighty-six US patents protecting AXSOME drugs.
Summary for Axsome
| US Patents: | 286 |
| Tradenames: | 3 |
| Ingredients: | 3 |
| NDAs: | 3 |
| Patent Litigation for Axsome: | See patent lawsuits for Axsome |
Drugs and US Patents for Axsome
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Axsome | AUVELITY | bupropion hydrochloride; dextromethorphan hydrobromide | TABLET, EXTENDED RELEASE;ORAL | 215430-001 | Aug 18, 2022 | RX | Yes | Yes | 11,197,839 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Axsome | SYMBRAVO | meloxicam; rizatriptan benzoate | TABLET;ORAL | 215431-001 | Jan 30, 2025 | RX | Yes | Yes | 10,653,777 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Axsome | SYMBRAVO | meloxicam; rizatriptan benzoate | TABLET;ORAL | 215431-001 | Jan 30, 2025 | RX | Yes | Yes | 10,512,692 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Axsome | AUVELITY | bupropion hydrochloride; dextromethorphan hydrobromide | TABLET, EXTENDED RELEASE;ORAL | 215430-001 | Aug 18, 2022 | RX | Yes | Yes | 12,194,036 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Axsome Malta | SUNOSI | solriamfetol hydrochloride | TABLET;ORAL | 211230-001 | Jun 17, 2019 | AB | RX | Yes | No | 12,263,145 | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Axsome
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Axsome Malta | SUNOSI | solriamfetol hydrochloride | TABLET;ORAL | 211230-002 | Jun 17, 2019 | 11,753,368 | ⤷ Start Trial |
| Axsome Malta | SUNOSI | solriamfetol hydrochloride | TABLET;ORAL | 211230-001 | Jun 17, 2019 | 10,351,517 | ⤷ Start Trial |
| Axsome Malta | SUNOSI | solriamfetol hydrochloride | TABLET;ORAL | 211230-001 | Jun 17, 2019 | 8,877,806 | ⤷ Start Trial |
| Axsome Malta | SUNOSI | solriamfetol hydrochloride | TABLET;ORAL | 211230-001 | Jun 17, 2019 | 9,604,917 | ⤷ Start Trial |
| Axsome Malta | SUNOSI | solriamfetol hydrochloride | TABLET;ORAL | 211230-002 | Jun 17, 2019 | 12,209,059 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Axsome Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 7148498 | ⤷ Start Trial |
| Israel | 245504 | ⤷ Start Trial |
| Japan | 2021107413 | ⤷ Start Trial |
| South Korea | 101931896 | ⤷ Start Trial |
| Australia | 2020207261 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Axsome Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2316456 | CR 2017 00062 | Denmark | ⤷ Start Trial | PRODUCT NAME: NALTREXON ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER NALTREXONHYDROCHLORID, OG BUPROPION ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER BUPROPIONHYDROCHLORID; REG. NO/DATE: EU/1/14/988 20150330 |
| 1890684 | SPC/GB20/017 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: SOLRIAMFETOL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREFERABLY A HYDROCHLORIDE SALT THEREOF; REGISTERED: UK EU/1/19/1408 (NI) 20200120; UK PLGB 31626/0003 20200120; UK PLGB 31626/0002 20200120 |
| 1890684 | 132020000000040 | Italy | ⤷ Start Trial | PRODUCT NAME: SOLRIAMFETOL O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE, PREFERIBILMENTE UN SUO SALE CLORIDRATO(SUNOSI); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/19/1408, 20200120 |
| 2316456 | 300918 | Netherlands | ⤷ Start Trial | PRODUCT NAME: NALTREXON OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, IN HET BIJZONDER NALTREXONHYDROCHLORIDE, EN BUPROPION OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, IN HET BIJZONDER BUPROPIONHYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/14/988 20150330 |
| 2316456 | 349 22-2017 | Slovakia | ⤷ Start Trial | PRODUCT NAME: KOMBINACIA NALTREXONU VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM A BUPROPIONU VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/14/988 20150330 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.

